Advanced Search

Tubulo-Interstitial Diseases of the Kidney Evaluations

To view Evaluated Articles, you must have an active subscription (or trial) and be signed in.
If you have an active subscription (or trial), please sign in. If your access has expired, you can subscribe at $9.95 per month. If you think you should be able to access this content, please contact us.

Sign in | Free Trial | Subscribe | Recommend to Library

New to F1000? See the Top Rated article below for a free preview of one of our Evaluated Articles.

SECTION HEADS

  • Photo of Marc De Broe

    Marc De Broe

    Medical School, Antwerp University, Edegem, Belgium

  • Photo of David Warnock

    David Warnock

    Division of Nephrology, University of Alabama, Birmingham, AL, USA

Section Topics

  • » Metabolic causes of tubulo-interstitial disease
  • » Reflux & obstructive nephropathy
  • » Renal interstitium & major features of chronic tubulo-interstitial nephritis
  • » Renal tubular disorders
  • » Toxic nephropathies
  • » Upper urinary tract infection

TOP RATED ARTICLE THIS WEEK [FREE TO VIEW]

6
The peroxisome proliferator-activated receptor-α agonist, BAY PP1, attenuates renal fibrosis in rats.

Boor P, Celec P, Martin IV, Villa L, ..., Albrecht-Küpper B, Ostendorf T, Heidland A, Šebeková K. Kidney Int. 2011 Dec; 80(11):1182-97

1 Evaluation, most recent by

Antonio Seguro, University of São Paulo, Brazil. F1000 Nephrology

INDIVIDUALS

Get instant access to evaluations from over 10,000 experts in biology and medicine by taking a free trial or an individual subscription.

Get a FREE Trial Subscribe for $9.95 per month

Already have a subscription? Sign in for instant access. If you are signed in but are not able to view content, your access has expired. Please take out a subscription or recommend F1000 to your librarian.

RECOMMENDATIONS

Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.

Recommend to your Librarian

LIBRARIANS & INFORMATION MANAGERS

Get an extended free trial supporting clinicians and researchers at your academic or corporate institution.

Request an Institutional Trial

FREE ACCESS

Your institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.